The Economics of Malaria Vaccine Development

Research output: Contribution to journalComment / DebateOtherpeer-review

2 Citations (Scopus)

Abstract

Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).

Original languageEnglish
Pages (from-to)154-156
Number of pages3
JournalTrends in Parasitology
Volume33
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Cite this